Skip to main content

BIOSENSORES PARA DESENTRAÑAR EL LEGADO Y EL FUTURO DE LA EPIGENETICA Y LA METASTASIS DEL CANCER

PID2019-103899RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

First electrochemical bioplatforms to determine anti-centromere B antibodies: Critical comparison between integrated and magnetic bead-assisted strategies using His-tag chemistry

  • Arévalo Pérez, Beatriz
  • Blázquez García, Marina
  • Valverde De La Fuente, Alejandro
  • Serafín González-Carrato, Verónica
  • Yáñez-Sedeño Orive, Paloma
  • Campuzano Ruiz, Susana
  • Pingarrón Carrazón, José Manuel
This work reports and compares the first electrochemical bioplatforms for determining anti-centromere B antibodies developed in magnetic microbead-assisted or integrated formats and proves the competitiveness of the nitrilotriacetic acid chemistry they exploit against common carbodiimide/succinimide-based one and their potential to determine serum target autoantibodies at clinically relevant levels.
Docta Complutense
Publication Artículo científico (JournalArticle)

Affinity bioelectroanalysis in cellular-level biomarker driven modern precision cancer diagnosis

  • Campuzano Ruiz, Susana
  • Gamella Carballo, María
  • Pedrero Muñoz, María
  • Pingarrón Carrazón, José Manuel
The increasingly prominent role played by precision, equitable and sustainable diagnosis, particularly of prevalent and highly heterogeneous diseases, based on the determination and characterization of biomarkers of cellular origin in liquid biopsy, such as whole cells, their secretomes and the exosomes they release, is unquestionable. Electrochemical biosensing and biosensors, mainly those involving affinity reactions, have emerged in recent years as competitive analytical alternatives to address these challenging targets versus other existing strategies in terms of simplicity, cost and compatibility with multiplexed or multi-omics point-of-care determinations. This review article aims to put on the table in a concise, accurate and updated way the fundamentals, versatility and opportunities provided by state-ofthe-art electrochemical biosensing (2018e2022) for the determination of these cellular-derived biomarkers. A more critical and personal view of the challenges to be faced in the shorter term and where future research and advances are expected to go is also given.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Electrochemical immunosensing of ST2: A checkpoint target in cancer diseases

  • Torrente-Rodríguez, Rebeca M.
  • Muñoz-San Martín, Cristina
  • Gamella, Maria
  • Pedrero, María
  • Martínez Bosch, Neus
  • Navarro Medrano, Pilar
  • García de Frutos, Pablo
  • Pingarrón, José M.
  • Campuzano, Susana
A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich immunoassay and disposable screen-printed carbon electrodes (SPCEs). Magnetic immunoconjugates built on the surface of carboxylic acid-microsized magnetic particles (HOOC-MBs) were used to selectively capture ST2. A biotinylated secondary antibody further conjugated with a streptavidin peroxidase conjugate (Strep-HRP) was used to accomplish the sandwiching of the target protein. The immune platform exhibits great selectivity and a low limit of detection (39.6 pg mL-1) for ST2, allowing the determination of soluble ST2 (sST2) in plasma samples from healthy individuals and patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) in only 45 min once the immunoconjugates have been prepared. The good correlation of the obtained results with those provided by an ELISA kit performed using the same immunoreagents demonstrates the potential of the developed strategy for early diagnosis and/or prognosis of the fatal PDAC disease., The financial support of PID2019-103899RB-I00 to S.C. (Spanish Ministerio de Ciencia e Innovación), RTI2018-095672-B-I00 to P.G-F (Spanish Ministerio de Ciencia, Innovación y Universidades) S2018/NMT-4349 to S.C. (Comunidad de Madrid) and PI20/00625 to P.N. (AES-ISCIII/FEDER) Research projects are gratefully acknowledged. C. Muñoz-San Martín acknowledges a predoctoral contract from Complutense University of Madrid. R.M. Torrente-Rodríguez acknowledges Talento-Contract from Comunidad de Madrid (2019-T2/IND-15965).
Repisalud
Publication Artículo científico (JournalArticle)

Magneto-controlled electrochemical immunosensing platform to assess the senescence-associated GDF-15 marker in colorectal cancer

  • Tejerina-Miranda, Sandra
  • Pérez-Ginés, Víctor
  • Torrente-Rodríguez, Rebeca M
  • Pedrero, María
  • Montero-Calle, Ana Maria
  • Pingarrón, José M
  • Barderas Manchado, Rodrigo
  • Campuzano, Susana
In this study, we report a novel electrochemical immunoplatform using magnetic micro-supports and screen-printed carbon electrodes (SPCEs), overcoming limitations of the methods reported to date, for the rapid and sensitive determination of GDF-15, a molecular marker associated with cellular senescence in aging and cancer development and prognosis. The immunoplatform incorporated a sandwich-type configuration with specific capture and biotinylated-detection antibodies and used a streptavidin–peroxidase (strep–HRP) enzymatic conjugate as label. After magnetic capturing the micro-supports with the sandwich HRP-labeled immunocomplexes onto the surface of a SPCE, the change in cathodic current was quantified in the presence of H2O2 and hydroquinone (HQ), showing a direct correlation with the GDF-15 concentration. The proposed bioplatform exhibited attractive performance characteristics, including a good reproducibility (RSD 4.3%), and a wide linear concentration dynamic range from 140 to 10 000 pg mL−1 with a low limit of detection (LOD) of 42 pg mL−1 for GDF-15 standards in buffered solutions. The selectivity of the developed method and the storage stability of the capturing immunoconjugates were noteworthy. Indeed, the immunoconjugates showed a reliable performance for over 28 days when stored in a refrigerator. The immunoplatform was applied to a cohort of 19 plasma samples representing the different stages of colorectal cancer (CRC). The method allowed efficient discrimination between healthy individuals and CRC patients, particularly those in advanced stages, within a rapid 75-minute timeframe. The immunoplatform also presents substantial advantages in terms of cost-effectiveness, assay time reduction, and simplicity compared to other available techniques.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Easily Multiplexable Immunoplatform to Assist Heart Failure Diagnosis through Amperometric Determination of Galectin‐3

  • Piguillem, Sofía V.
  • Gamella, María
  • García de Frutos, Pablo
  • Batlle, Montserrat
  • Yáñez-Sedeño, Paloma
  • Messina, Germán A.
  • Fernández‐Baldo, Martín A.
  • Campuzano, Susana
  • Pedrero, María
  • Pingarrón, José Manuel
his work reports the first electrochemicalimmunoassay involving magnetic microbeads (MBs) forthe determination of galectin-3 (Gal-3), a -galactosidase-binding lectin that acts as mediator of heart failure (HF).MBs-captured sandwich-type immune complexes andamperometric detection at disposable screen-printed car-bon electrodes were used. The immunoplatform showed adetection limit of 8.3 pgmL 1, good reproducibility, andexcellent selectivity. The endogenous concentration ofGal-3 in human plasma from HF patients was determinedwith results in agreement with those obtained usingELISA. The multiplexing feasibility of the developedimmunoplatform was demonstrated for the simultaneousdetermination of Gal-3 and N-terminal pro-brain natriu-retic peptide (NT-proBNP), This work is part of the POSITION-II project funded bythe ECSEL Joint Undertaking under grant number Ecsel-783132-Position-II-2017-IA; www.position-2.eu, andPID2019-103899RB-I00 (Ministerio de Ciencia e Innova-ción), and of the NANOCARDIOFLEX Project (RetosColaboración RTC-2015-4184-1, cofinanced by the Minis-terio de Economía y Competitividad and FEDER “unamanera de hacer Europa”). The financial support of theRTI2018-096135-B-I00 (Ministerio de Ciencia, Innovacióny Universidades) and PID2019-103899RB-I00 (Ministeriode Ciencia e Innovación) and Research Projects and theTRANSNANOAVANSENS-CM Program from the Co-munidad de Madrid (Grant S2018/NMT-4349) are alsogratefully acknowledged. S.V.P acknowledges the doctor-al fellowship from the Fundación Carolina, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multiplexed biosensing diagnostic platforms detecting autoantibodies to tumor-associated antigens from exosomes released by CRC cells and tissue samples showed high diagnostic ability for colorectal cancer

  • Montero-Calle, Ana
  • Aranguren-Abeigon, Itziar
  • Garranzo Asensio, María
  • Povés, Carmen
  • Fernandez-Aceñero, M. Jesús
  • Martínez-Useros, Javier
  • Sanz, Rodrigo
  • Dziaková, Jana
  • Rodríguez-Cobos, Javier
  • Solís-Fernández, Guillermo
  • Povedano, Eloy
  • Gamella, María
  • Torrente-Rodríguez, Rebeca M.
  • Alonso-Navarro, Miren
  • Ríos, Vivian de los
  • Casal, J. Ignacio
  • Domínguez-Muñoz, Gemma
  • Guzmán-Aránguez, Ana I.
  • Peláez-García, Alberto
  • Pingarrón, José Manuel
  • Campuzano, Susana
  • Barderas, Rodrigo
20 p.-9 fig.-2 tab., Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. The 5-year survival rate of CRC patients depends on the stage at diagnosis, being higher than 80% when CRC is diagnosed in the early stages but lower than 10% when CRC is diagnosed in advanced stages. Autoantibodies against specific CRC autoantigens (tumor-associated antigens (TAAs)) in the sera of patients have been widely demonstrated to aid in early diagnosis. Thus, we herein aim to identify autoantigens target of autoantibodies specific to CRC that possess a significant ability to discriminate between CRC patients and healthy individuals by means of liquid biopsy. To that end, we examined the protein content of the exosomes released by five CRC cell lines and tissue samples from CRC patients by means of immunoprecipitation coupled with mass spectrometry analysis. A total of 103 proteins were identified as potential autoantigens specific to CRC. After bioinformatics and meta-analysis, we selected 15 proteins that are more likely to be actual CRC autoantigens in order to evaluate their role in CRC prognosis by Western blot (WB) and immunohistochemistry (IHC). We found dysregulation at the protein level for 11 of these proteins in both tissue and plasma exosome samples from patients, along with an association of nine of these proteins with CRC prognosis. After validation, all but one showed a statistically significant high diagnostic ability to distinguish CRC patients and individuals with premalignant lesions from healthy individuals, either by luminescence Halotag-based beads, or by a multiplexed biosensing platform involving the use of magnetic microcarriers as solid support modified with covalently immobilized Halotag fusion proteins constructed for CRC detection. Taken together, our results highlight the usefulness of the approach defined here to identify the TAAs specific to chronic diseases; they also demonstrate that the measurement of autoantibody levels in plasma against the TAAs identified here could be integrated into a point-of-care (POC) device for CRC detection with high diagnostic ability., This work was supported by the financial support of the PI17CIII/00045 and PI20CIII/00019 grants from the AES-ISCIII program to R.B. The financial support of the PID2019-103899RB-I00 (Ministerio de Ciencia e Innovación) Research Project and the TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (S2018/NMT-4349) to S.C. are gratefully acknowledged. G.D. acknowledges the financial support of PI15/00246 grant of the FIS and Cátedra UAM-Roche en Medicina de Innovación. The FPU predoctoral contract to A.M-C. is supported by the Spanish Ministerio de Educación, Cultura y Deporte. G.S-F. is recipient of a predoctoral contract (1193818N) supported by The Flanders Research Foundation (FWO). M.A-N. was supported by a contract of the Programa Operativo de Empleo Juvenily la Iniciativa de Empleo Juvenil (YEI) with the participation of the Consejería de Educación, Juventud y Deporte de la Comunidad de Madrid y del Fondo Social Europeo. The predoctoral contract from the Spanish Ministerio de Economía y Competitividad (BES-2016-076606, E.P.) and Talento-Contract from Comunidad de Madrid (2019-T2/IND-15965, R.M.T-R.) are also gratefully acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Electrochemical immunosensing of st2: A checkpoint target in cancer diseases

  • Torrente-Rodríguez, Rebeca M.
  • Muñoz-San Martín, Cristina
  • Gamella, María
  • Pedrero, María
  • Martínez-Bosch, Neus
  • Navarro Medrano, Pilar
  • García de Frutos, Pablo
  • Pingarrón, José Manuel
  • Campuzano, Susana
A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich immunoassay and disposable screen-printed carbon electrodes (SPCEs). Magnetic immunoconjugates built on the surface of carboxylic acid-microsized magnetic particles (HOOC-MBs) were used to selectively capture ST2. A biotinylated secondary antibody further conjugated with a streptavidin peroxidase conjugate (Strep-HRP) was used to accomplish the sandwiching of the target protein. The immune platform exhibits great selectivity and a low limit of detection (39.6 pg mL ) for ST2, allowing the determination of soluble ST2 (sST2) in plasma samples from healthy individuals and patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) in only 45 min once the immunoconjugates have been prepared. The good correlation of the obtained results with those provided by an ELISA kit performed using the same immunoreagents demonstrates the potential of the developed strategy for early diagnosis and/or prognosis of the fatal PDAC disease., This research was funded by Spanish Ministerio de Ciencia e Innovación. PID2019- 103899RB-I00, Spanish Ministerio de Ciencia, Innovación y Universidades, RTI2018-095672-B-I00, Comunidad de Madrid, S2018/NMT-4349, and AES-ISCIII/FEDER, PI20/00625
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ultrasensitive detection of soy traces by immunosensing of glycinin and β-conglycinin at disposable electrochemical platforms

  • Blázquez-García, Marina
  • Arévalo, Beatriz
  • Serafín, Verónica
  • Benedé, Sara
  • Mata, Luis
  • Galán-Malo, Patricia
  • Segura-Gil, Isabel
  • Pérez, María Dolores
  • Pingarrón, José Manuel
This work reports the first electrochemical bioplatform for the determination of soy traces in food. The bioplatform involves sandwich-type immunoassays using specific antibodies for β-conglycinin and glycinin, which are the main allergenic soy proteins, and carboxylic acid-modified magnetic microbeads. Amperometric detection at −0.20 V (vs. an Ag pseudo-reference electrode) was performed using single or dual screen-printed carbon electrodes and the H2O2/hydroquinone (HQ) system. The measured variation in the cathodic current was directly proportional to the concentration of target allergenic proteins. The developed bioplatforms exhibit a good selectivity and sensitivity providing limits of detection (LOD) values of 0.03 and 0.02 ng mL−1 for β-conglycinin and glycinin, respectively. The determination of both proteins can be carried out in only 1.5 h. The electrochemical bioplatforms allow their accurate determinations (with results statistically comparable to those provided by ELISA methodologies) in raw cookie dough and baked cookies enriched with soy flour. The results obtained confirm, in a pioneering way with electrochemical biosensors, the possibility of discriminating samples incurred with as little as 0.0005 ppm of a food allergen in model cookie extracts., The financial support of PID2019-103899RB-I00 to S.C., (Spanish Ministerio de Ciencia e Innovación) Research Project, and TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349) to S.C. are gratefully acknowledged. S.B. acknowledges a Juan de la Cierva Incorporación contract (Ref.: IJCI-2017-31345) from the Spanish Ministerio de Economía, Industria y Competitividad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Electrochemical immunosensing of Growth arrest-specific 6 in human plasma and tumor cell secretomes

  • Muñoz-San Martín, Cristina
  • Pérez-Ginés, Víctor
  • Torrente-Rodríguez, Rebeca M.
  • Gamella, María
  • Solís-Fernández, Guillermo
  • Montero-Calle, Ana
  • Pedrero, María
  • Serafín, Verónica
  • Martínez-Bosch, Neus
  • Navarro Medrano, Pilar
  • García de Frutos, Pablo
  • Batlle, Montserrat
  • Barderas, Rodrigo
  • Pingarrón, José Manuel
  • Campuzano, Susana
Growth arrest-specific 6 (GAS6) protein plays a key role in processes related to proliferation, inflammation, angiogenesis, and atherosclerotic plaque formation. In addition, it has been reported that plasma levels of GAS6 are related to cancer prognosis and other relevant pathologies, such as heart failure or sepsis. We report here the first electrochemical immunoplatform for the determination of GAS6, which has demonstrated to be competitive with other available methodologies in terms of cost, simplicity, and decentralized application. The developed immunoplatform involves a sandwich immunoassay using magnetic microparticles (MBs) and uses amperometric detection at disposable screen-printed carbon electrodes (SPCEs). The MBs were modified with an antibody specific to GAS6 for its selective capture, which is further recognized by a biotinylated secondary antibody subsequently labeled with a streptavidin-horseradish peroxidase (Strep-HRP) conjugate. The electrochemical detection was carried out using the hydroquinone (HQ)/H2O2 system. The developed bioplatform exhibits a great selectivity and low limit of detection (27 pg/mL) that allowed the determination of the GAS6 circulating level in plasma samples from patients suffering heart failure (HF) and diagnosed with pancreatic ductal adenocarcinoma (PDAC), as well as the determination of the target protein in raw secretomes of human colorectal cancer cell lines., This work is part of the POSITION-II project fundedby the ECSEL Joint Undertaking under grant numberEcsel-783132-Position-II-2017-IA;www.position-2.eu,and PCI2018-093067 (Spanish Ministerio de Ciencia eInnovación) to M.P. The financial support of PID2019-103899RB-I00 (Spanish Ministerio de Ciencia e Inno-vación) Research Project to S.C., PI17CIII/00045 andPI20CIII/00019 grants from the AES-ISCIII program toR.B. and the TRANSNANOAVANSENS-CM Program fromthe Comunidad de Madrid (Grant S2018/NMT-4349) toS.C., RTI2018-095672-B-I00 (Spanish Ministerio de Cienciae Innovación) to P.G.F.; Fundació la Marató de TV3 project081010toM.B.; researchprojectPI20/00625,fromtheAES-ISCIII/FEDER program, to P.N, are gratefully acknowl-edged. A. Montero-Calle acknowledges the support of theFPU predoctoral contracts by the Spanish Ministerio deEducación, Cultura y Deporte. G.S-F. is recipient of a pre-doctoral contract (grant number 1193818N) supported byThe Flanders Research Foundation (FWO). C. Muñoz-SanMartín acknowledges a predoctoral contract from Complutense University of Madrid. R.M. Torrente-Rodríguezacknowledges a Talento-Contract from Comunidad deMadrid (2019-T2/IND-15965).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Electrochemical immunoplatform to help managing pancreatic cancer

  • Pérez-Ginés, Víctor
  • Torrente-Rodríguez, Rebeca M.
  • Pedrero, María
  • Martínez-Bosch, Neus
  • García de Frutos, Pablo
  • Navarro Medrano, Pilar
  • Pingarrón, José Manuel
  • Campuzano, Susana
Pancreatic ductal adenocarcinoma (PDAC) is the solid tumor with the worst prognosis, representing today the third cause of cancer-related deaths in developed countries and expected to be the second in 2030. Today, CA19-9 remains the only clinically used marker for management of PDAC (FDA-approved as a disease monitoring marker). This work reports a disposable amperometric immunoplatform for the determination of CA19-9. The immunoplatform skilfully combines the advantages of magnetic microsupports (MBs) for implementation of the immunoassay and amperometric transduction on screen-printed carbon electrodes (SPCEs). The method involves the preparation of sandwich immunocomplexes enzymatically labeled with the enzyme horseradish peroxidase (HRP) on the MBs and uses a detection antibody conjugated to HRP. Once the HRP-labeled sandwich immunocomplexes-bearing MBs were trapped on the SPCE surface, the variation of the cathodic current was measured in the presence of HO and hydroquinone (HQ), which was directly proportional to the concentration of CA19-9. Under the optimized experimental conditions, the immunoplatform allowed the amperometric determination of CA19-9 standards over the 5.0 to 500 U mL concentration range, with a limit of detection (LOD) value of 1.5 U mL in 1 h. The method exhibits good reproducibility and selectivity and the magnetic immunoconjugates shows a good storage stability. The immunoplatform was applied to the determination of CA19-9 in serum samples of a medium-sized cohort (22 individuals) of healthy subjects and patients diagnosed with PDAC. The obtained results demonstrated the immunoplatform ability to discriminate both types of individuals within 1 h after sample dilution. The developed immunoplatform represents an improvement in terms of cost, applicability and accessibility compared to the ELISA-based techniques currently used in the clinic., The financial support of PID2019-103899RB-I00 and the TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349) to S.C. and from the Spanish Ministry of Science and Innovation (MICINN)/ Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF) (PI20/00625) to P.N. are gratefully acknowledged. V.P.G. acknowledges a predoctoral contract from Universidad Complutense de Madrid. We would also like to thank Dr. L. Visa (Oncology Department, Hospital del Mar), Dr. L.E. Barranco (Digestive Department, Hospital del Mar) and D. Zafra Puerta (Nursing Department, Hospital del Mar) for their valuable help with sample collection, as well as patients and their families who were enrolled in the project.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pursuing precision in medicine and nutrition: the rise of electrochemical biosensing at the molecular level

  • Campuzano, Susana
  • Barderas, Rodrigo
  • Moreno-Casbas, Maria Teresa
  • Almeida, Ángeles
  • Pingarrón, José Manuel
In the era that we seek personalization in material things, it is becoming increasingly clear that the individualized management of medicine and nutrition plays a key role in life expectancy and quality of life, allowing participation to some extent in our welfare and the use of societal resources in a rationale and equitable way. The implementation of precision medicine and nutrition are highly complex challenges which depend on the development of new technologies able to meet important requirements in terms of cost, simplicity, and versatility, and to determine both individually and simultaneously, almost in real time and with the required sensitivity and reliability, molecular markers of different omics levels in biofluids extracted, secreted (either naturally or stimulated), or circulating in the body. Relying on representative and pioneering examples, this review article critically discusses recent advances driving the position of electrochemical bioplatforms as one of the winning horses for the implementation of suitable tools for advanced diagnostics, therapy, and precision nutrition. In addition to a critical overview of the state of the art, including groundbreaking applications and challenges ahead, the article concludes with a personal vision of the imminent roadmap., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The financial support of PID2019-103899RB-I00 (Spanish Ministerio de Ciencia e Innovación), and PMP22/00084, PI17CIII/00045, PI20CIII/00019 and PI22/00727 (AES-ISCIII) co-founded with FEDER funds Research Projects and the TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349) are gratefully acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Electrochemical bioplatform to manage alpha-gal syndrome by tracking the carbohydrate allergen in meat

  • Ruiz-Valdepeñas Montiel, Víctor
  • Gamella, María
  • Blázquez-García, Marina
  • Serafín, Verónica
  • Molina, Elena
  • Pingarrón, José Manuel
  • Benedé, Sara
  • Campuzano, Susana
This work presents the first bioplatform described to date for the determination of galactose-α-1,3-galactose (α-Gal), a non-primate mammalian oligosaccharide responsible for almost all cases of red meat allergy. The bioplatform is based on the implementation of an indirect competitive immunoassay and enzymatic labeling with the enzyme horseradish peroxidase (HRP) built on the surface of magnetic microparticles (MBs) and amperometric transduction on screen-printed carbon electrodes (SPCEs) using the H2O2/hydroquinone (HQ) system. The target α-Gal competed with biotinylated α-Gal immobilized on the surface of neutravidin-modified MBs for the limited immunorecognition sites of a detection antibody enzymatically labeled with an HRP-conjugated secondary antibody. The resulting magnetic immunoconjugates were trapped on the surface of the SPCE working electrode and amperometric transduction was performed, providing a cathodic current variation inversely proportional to the concentration of α-Gal in the analyzed sample. The developed biotool was optimized, characterized and applied with satisfactory results to the determination of the target allergen in different samples of raw and processed meats., The financial support of Grant PID2019-103899RB-I00 funded by MCIN/AEI/10.13039/501100011033, and TRANSNANOAVANSENS-CM Program from the Comunidad de Madrid (Grant S2018/NMT-4349) to S.C. are gratefully acknowledged., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Electrochemical immunosensing of ST2: A checkpoint target in cancer diseases

  • Torrente-Rodríguez, Rebeca M.
  • Muñoz-San Martín, Cristina
  • Gamella, Maria
  • Pedrero, María
  • Martínez Bosch, Neus
  • Navarro Medrano, Pilar
  • García de Frutos, Pablo
  • Pingarrón, José M.
  • Campuzano, Susana
A magnetic beads (MB)-involved amperometric immunosensor for the determination of ST2, a member of the IL1 receptor family, is reported in this work. The method utilizes a sandwich immunoassay and disposable screen-printed carbon electrodes (SPCEs). Magnetic immunoconjugates built on the surface of carboxylic acid-microsized magnetic particles (HOOC-MBs) were used to selectively capture ST2. A biotinylated secondary antibody further conjugated with a streptavidin peroxidase conjugate (Strep-HRP) was used to accomplish the sandwiching of the target protein. The immune platform exhibits great selectivity and a low limit of detection (39.6 pg mL-1) for ST2, allowing the determination of soluble ST2 (sST2) in plasma samples from healthy individuals and patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) in only 45 min once the immunoconjugates have been prepared. The good correlation of the obtained results with those provided by an ELISA kit performed using the same immunoreagents demonstrates the potential of the developed strategy for early diagnosis and/or prognosis of the fatal PDAC disease., The financial support of PID2019-103899RB-I00 to S.C. (Spanish Ministerio de Ciencia e Innovación), RTI2018-095672-B-I00 to P.G-F (Spanish Ministerio de Ciencia, Innovación y Universidades) S2018/NMT-4349 to S.C. (Comunidad de Madrid) and PI20/00625 to P.N. (AES-ISCIII/FEDER) Research projects are gratefully acknowledged. C. Muñoz-San Martín acknowledges a predoctoral contract from Complutense University of Madrid. R.M. Torrente-Rodríguez acknowledges Talento-Contract from Comunidad de Madrid (2019-T2/IND-15965).
Docta Complutense
Publication Artículo científico (JournalArticle)

Multiplexed magnetic beads-assisted amperometric bioplatforms for global detection of methylations in nucleic acids

  • Povedano Muñumel, Eloy
  • Gamella Carballo, María
  • Torrente Rodríguez, Rebeca Magnolia
  • Ruiz Valdepeñas Montiel, Víctor
  • Montero-Calle, Ana
  • Solís-Fernández, Guillermo
  • Navarro Villoslada, Fernando
  • Pedrero Muñoz, María
  • Peláez-García, Alberto
  • Mendiola, Marta
  • Hardisson, David
  • Feliú, Jaime
  • Barderas Manchado, Rodrigo
  • Pingarrón Carrazón, José Manuel
This work reports the first electrochemical bioplatform developed for the multidetection of 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) in DNA, DNA N6-methyladenine (6mA) and RNA N6-methyladenosine (m6A) methylations at global level. Direct competitive immunoassays were implemented on the surface of magnetic beads (MBs) and optimized for the single amperometric determination of different targets varying in length, sequence and number of methylations on screenprinted carbon electrodes. After evaluating the sensitivity and selectivity of such determinations and the confirmation of no cross-reactivity, a multiplexed disposable platform allowing the simultaneous determination of the mentioned four methylation events in only 45 min has been prepared. The multiplexed bioplatform was successfully applied to the determination of m6A in cellular total RNA and of 5-mC, 5-hmC and 6mA in genomic DNA extracted from tissues. The developed bioplatform showed its usefulness to discriminate the aggressiveness of cancerous cells and between healthy and tumor tissues of colorectal cancer patients.
Docta Complutense
Publication Artículo científico (JournalArticle)

Magnetic microbeads-based amperometric immunoplatform for the rapid and sensitive detection of N6-methyladenosine to assist in metastatic cancer cells discrimination

  • Povedano Muñumel, Eloy
  • Gamella Carballo, María
  • Torrente Rodríguez, Rebeca Magnolia
  • Montero-Calle, Ana
  • Pedrero Muñoz, María
  • Solís-Fernández, Guillermo
  • Navarro Villoslada, Fernando
  • Barderas Manchado, Rodrigo
  • Campuzano Ruiz, Susana
  • Pingarrón Carrazón, José Manuel
This work describes the preparation of an immunoplatform for the sensitive and selective determination of N6-methyladenosine (m6A). The simple and fast protocol involves for the first time the use of micromagnetic immunoconjugates to establish a direct competitive assay between the m6A target and a biotinylated RNA oligomer bearing a single m6A enzymatically labelled with a commercial conjugate of streptavidin-peroxidase (Strep-HRP) as tracer. The cathodic current change measured in the presence of H2O2/hydroquinone (HQ) at screen-printed carbon electrodes (SPCEs) upon surface capturing the magnetic bioconjugates is inversely proportional to the m6A target concentration. After evaluating the effect of key variables, the analytical characteristics were established for the determination of three different targets: the N6-methyladenosine-5′ -triphosphate (m6ATP) ribonucleotide, a short synthetic RNA oligomer bearing a single m6A and the positive control provided in a commercial colorimetric kit for m6A-RNA quantification. The obtained results show that this immunoplatform is competitive with other methods reported to date, achieving an improved sensitivity (limit of detection of 0.9 pM for the short synthetic oligomer) using a much simpler and faster protocol (~1 h) and disposable electrodes for the transduction. Furthermore, the applicability for discriminating the metastatic potential of cancer cells by directly analyzing a small amount of raw total RNA without enriching or fragmenting was also preliminary assessed.
Docta Complutense
Publication Artículo científico (JournalArticle)

Bringing to light the importance of the mirna methylome in colorectal cancer prognosis through electrochemical bioplatforms

  • Povedano Muñumel, Eloy
  • Ruiz Valdepeñas Montiel, Víctor
  • Sebuyoya, Ravery
  • Torrente Rodríguez, Rebeca Magnolia
  • Garranzo Asensio, María
  • Montero Calle, Ana
  • Pingarrón Carrazón, José Manuel
  • Barderas Manchado, Rodrigo
  • Bartosik, Martin
  • Campuzano Ruiz, Susana
This work reports the first electrochemical bioplatforms developed for the determination of the total contents of either target miRNA or methylated target miRNA. The bioplatforms are based on the hybridization of the target miRNA with a synthetic biotinylated DNA probe, the capture of the formed DNA/miRNA heterohybrids on the surface of magnetic microcarriers, and their recognition with an antibody selective to these heterohybrids or to the N6-methyladenosine (m6A) epimark. The determination of the total or methylated target miRNA was accomplished by labeling such secondary antibodies with the horseradish peroxidase (HRP) enzyme. In both cases, amperometric transduction was performed on the surface of disposable electrodes after capturing the resulting HRP-tagged magnetic bioconjugates. Because of their increasing relevance in colorectal cancer (CRC) diagnosis and prognosis, miRNA let-7a and m6A methylation were selected. The proposed electrochemical bioplatforms showed attractive analytical and operational characteristics for the determination of the total and m6A-methylated target miRNA in less than 75 min. These bioplatforms, innovative in design and application, were applied to the analysis of total RNA samples extracted from cultured cancer cells with different metastatic profiles and from paired healthy and tumor tissues of patients diagnosed with CRC at different stages. The obtained results demonstrated, for the first time using electrochemical platforms, the potential of interrogating the target miRNA methylation level to discriminate the metastatic capacities of cancer cells and to identify tumor tissues and, in a pioneering way, the potential of the m6A methylation in miRNA let-7a to serve as a prognostic biomarker for CRC.
Docta Complutense
Publication Artículo científico (JournalArticle)

Electrochemical Affinity Biosensors: Pervasive Devices with Exciting Alliances and Horizons Ahead

  • Campuzano Ruiz, Susana
  • Pingarrón Carrazón, José Manuel
Electrochemical affinity biosensors are evolving at breakneck speed, strengthening and colonizing more and more niches and drawing unimaginable roadmaps that increasingly make them protagonists of our daily lives. They achieve this by combining their intrinsic attributes with those acquired by leveraging the significant advances that occurred in (nano)materials technology, bio(nano)materials and nature-inspired receptors, gene editing and amplification technologies, and signal detection and processing techniques. The aim of this Perspective is to provide, with the support of recent representative and illustrative literature, an updated and critical view of the repertoire of opportunities, innovations, and applications offered by electrochemical affinity biosensors fueled by the key alliances indicated. In addition, the imminent challenges that these biodevices must face and the new directions in which they are envisioned as key players are discussed.
Docta Complutense
Publication Artículo científico (JournalArticle)

Anti-double stranded DNA antibodies: Electrochemical isotyping in autoimmune and neurological diseases

  • Arévalo Pérez, Beatriz
  • Serafín González-Carrato, Verónica
  • Garranzo Asensio, Maria
  • Montero Calle, Ana
  • Barderas Manchado, Rodrigo
  • Yáñez-Sedeño Orive, Paloma
  • Campuzano Ruiz, Susana
  • Pingarrón Carrazón, José Manuel
This work reports the first amperometric biosensor for the simultaneous determination of the single or total content of the most relevant human immunoglobulin isotypes (hIgs) of anti-dsDNA antibodies, dsDNA-hIgG, dsDNA-hIgM, dsDNA-hIgA and dsDNA-three hIgs, which are considered relevant biomarkers in prevalent autoimmune diseases such as systemic lupus erythematosus (SLE) as well as of interest in neurodegenerative diseases such as Alzheimer's disease (AD). The bioplatform involves the use of neutravidin-functionalized magnetic microparticles (NA-MBs) modified with a laboratory-prepared biotinylated human double-stranded DNA (b-dsDNA) for the efficient capture of specific autoantibodies that are enzymatically labeled with horseradish peroxidase (HRP) enzyme using specific secondary antibodies for each isotype or a mixture of secondary antibodies for the total content of the three isotypes. Transduction was performed by amperometry (−0.20 V vs. the Ag pseudo-reference electrode) using the H2O2/hydroquinone (HQ) system after trapping the resulting magnetic bioconjugates on each of the four working electrodes of a disposable quadruple transduction platform (SP4CEs). The bioplatform demonstrated attractive operational characteristics for clinical application and was employed to determine the individual or total hIgs classes in serum from healthy individuals and from patients diagnosed with SLE and AD. The target concentrations in AD patients are provided for the first time in this work. In addition, the results for SLE patients and control individuals agree with those obtained by applying ELISA tests as well as with the clinical ranges reported by other authors, using individual detection methodologies restricted to centralized settings or clinical laboratories.
Docta Complutense
Publication Artículo científico (JournalArticle)

Pursuing precision in medicine and nutrition: the rise of electrochemical biosensing at the molecular level

  • Campuzano Ruiz, Susana
  • Barderas Manchado, Rodrigo
  • Moreno-Casbas, María Teresa
  • Almeida, Ángeles
  • Pingarrón Carrazón, José Manuel
In the era that we seek personalization in material things, it is becoming increasingly clear that the individualized management of medicine and nutrition plays a key role in life expectancy and quality of life, allowing participation to some extent in our welfare and the use of societal resources in a rationale and equitable way. The implementation of precision medicine and nutrition are highly complex challenges which depend on the development of new technologies able to meet important requirements in terms of cost, simplicity, and versatility, and to determine both individually and simultaneously, almost in real time and with the required sensitivity and reliability, molecular markers of different omics levels in biofluids extracted, secreted (either naturally or stimulated), or circulating in the body. Relying on representative and pioneering examples, this review article critically discusses recent advances driving the position of electrochemical bioplatforms as one of the winning horses for the implementation of suitable tools for advanced diagnostics, therapy, and precision nutrition. In addition to a critical overview of the state of the art, including groundbreaking applications and challenges ahead, the article concludes with a personal vision of the imminent roadmap.
Docta Complutense
Publication Artículo científico (JournalArticle)

Early and differential autoimmune diseases diagnosis by interrogating specific autoantibody signatures with multiplexed electrochemical bioplatforms

  • Arévalo Pérez, Beatriz
  • Serafín González-Carrato, Verónica
  • Garranzo Asensio, María
  • Barderas Manchado, Rodrigo
  • Yáñez-Sedeño Orive, Paloma
  • Campuzano Ruiz, Susana
  • Pingarrón Carrazón, José Manuel
This work reports the first bioplatform to assist in the early and reliable diagnosis of autoimmune diseases by quadruple determination of autoantibodies (Abs) produced against extractable nuclear antigens (ENAs): La/SSBAbs, Ro/SSA-Abs, U1snRNP70-Abs and smRNP-Abs. The bioplatform involves indirect immunoassays on the surface of magnetic microcarriers (independent batches for each of the target autoantibodies) and amperometric transduction using the H2O2/hydroquinone (HQ) system on a disposable multiple electrode platform. The magnetic microcarriers were modified with the corresponding antigens using His-tag and carbodiimide/succinimide chemistries and employed for the selective capture of the corresponding autoantibodies. Thereafter, they were enzymatically labelled with a secondary antibody conjugated with horseradish peroxidase (HRP) and magnetically captured on each of the working surfaces of the quadruple platform. The evaluation of the analytical and operational characteristics of the bioplatform for the amperometric determination of standards, performed under optimized experimental conditions, confirmed the bioplatform competitiveness in terms of sensitivity and point-of-care application compared to commercially available ELISA methodologies for the single determination of target Abs. The developed bioplatform was applied to the analysis of serum samples from healthy individuals and from patients with two prevalent autoimmune diseases (systemic lupus erythematosus, SLE, and Sjogren ¨ ’s syndrome, SS). The obtained results proved the potential of the bioplatform for the differential diagnosis of these two autoimmune diseases through the accurate, simple, and rapid multidetermination of the four target Abs.
Docta Complutense
Publication Artículo científico (JournalArticle)

Electrochemical bioanalysis: All that still hides the tip of the iceberg

  • Campuzano Ruiz, Susana
  • Pingarrón Carrazón, José Manuel
The tremendous advances in electrochemical biosensing that have occurred recently, highlighting as never before the versatility and adaptability of the resulting biotools, together with the innovations in the natural-inspired bioreceptor production, electrode substrate fabrication, miniaturizable electronics, materials science, digitization and artificial intelligence that can empower electrochemical biosensing have changed the perception of what we have seen and what electrochemical biosensing can offer us. This minireview aims to give a brief and current bird's eye view of the most recent innovations in electrochemical biosensing involving design, manufacturing, characteristics and applications, supported by references to broaden and deepen concepts. The goal is to convince the reader that electrochemical bioanalysis has so far only shown us a small part of its wide and multifaceted world of which we will continue to be privileged witnesses in the coming years.